Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
50,796,845
-
Shares change
-
+564,486
-
Total reported value, excl. options
-
$57,906,145
-
Value change
-
+$685,292
-
Put/Call ratio
-
47%
-
Number of buys
-
24
-
Number of sells
-
30
-
Price
-
$1.14
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2023
As of 30 Sep 2023 Akebia Therapeutics, Inc. - Common Stock (AKBA) had 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 50,796,845 shares of stock of the company.
Largest 10 holders included Alerce Investment Management, L.P., VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, JACOBS LEVY EQUITY MANAGEMENT, INC, FEDERATED HERMES, INC., and VICTORY CAPITAL MANAGEMENT INC.
This table shows 72 institutional shareholders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.